🕒 Last update: loading…

Stock Relmada Therapeutics, Inc. RLMD

Relmada Therapeutics, Inc. — Investlytic score 2/5 on the five criteria.

-
-
40/ 100
Score Investlytic · 5 criteria

Analysis in progress…

Investlytic score: 2/5 criteria met.

  • ✅ Price trend passed
  • ❌ Growth failed
  • ✅ Debt passed
  • ❌ P/E failed
  • ❌ Correction failed

Price trend

Overall trend (8 years): the price has been multiplied by at least 1.5.

Price change 2018 → 2019: 747.83%

Price change 2019 → 2020: -17.82%

Price change 2020 → 2021: -29.64%

Price change 2021 → 2022: -80.65%

Price change 2022 → 2023: 18.05%

Price change 2023 → 2024: -49.51%

Price change 2024 → 2025: 828.85%

Price change 2025 → 2026: 9.94%

Price change 2026 (year to date): 21.51%

Financial growth

Revenue CAGR (8 years): N/A

Earnings CAGR (8 years): N/A

Growth status: insufficient data or negative trend.

Debt

Debt-to-equity ratio: 0.00

Debt/equity < 0.5 (maximum threshold).

P/E (Price/Earnings)

P/E ratio: -4.00

P/E > 25.0 (maximum threshold).

Correction (6 months)

Current correction: 32.44% from the high over 6 months.

Excessive correction (> 20.0%).

WATCH
The stock is currently being evaluated.

Criteria of the Investlytic model

- / 5
🔒

Investlytic rating reserved for members

Score out of 100, model verdict (buy, watch, sell) and details of the 5 criteria · visible with a free account.

02

Price trend

Price & trend

Interactive chart →
Loading chart…

⚖️ Comparison with the market

All stocks →
StockP/EDette/FPRevenue growthRating
Relmada Therapeutics, Inc.–0.00–🔒
Boiron S.A.13.20.08−0.2 %–
Senseonics Holdings, Inc.–0.68+89.0 %–
Equasens S.A.10.60.21+6.5 %–
Valneva SE–1.95+22.4 %–

Data from the Investlytic screener. The rating of the stock being viewed is reserved for members.

03

Detailed analysis · Price trend

-

🔒

Reserved for members

Global model trend and annual price variations · visible with a free account.

04

Revenues & profits

Revenue and net income

🔒

Reserved for members

Chart of revenues and net income over 8 periods · real data, no estimates.

05

Financial indicators

🔒

Reserved for members

18 financial indicators analyzed by groups of criteria: valuation, profitability, growth, solidity, dividend, and momentum.

06

Annual financial statements

Fiscal yearRevenueNet income Net marginEPSRevenue growth
🔒

Reserved for members

Complete annual financial statements: revenue, net income, margin, and EPS over 8 fiscal years.

+

Key reported figures

Revenue, net income and net margin reported by Relmada Therapeutics, Inc. over the latest fiscal years.

Revenue
5,129 USD
fiscal year 2013
Net income
-45,015 USD
fiscal year 2013
Net margin
-877.7 %
fiscal year 2013
Market cap
449 m USD
Fiscal yearRevenueNet incomeNet marginRevenue growth
20127,941-12,052-151.8 %n/a
20135,129-45,015-877.7 %-35.4 %

Amounts converted to USD. Source: published annual accounts, collected on 13/11/2026.

+

Accounts and financial health

Balance sheet and cash flow published by Relmada Therapeutics, Inc. over the last fiscal years, strength scores and valuation by discounted cash flow (DCF).

Overview
average accounts
according to Altman Z, Piotroski and net debt
Altman Z-score
18.07
safe zone (above 2.99)
Piotroski Score
2 / 9
0 to 3: fragile accounts
Net Debt / EBITDA
0.09 x
low debt
Fiscal year20212022202320242025
Cash and investments212 m148 m96.3 m44.9 m93.0 m
Total Debt00000
Net Debt-44.4 m-5.4 m-4.1 m-3.9 m-3.5 m
Equity208 m140 m85.4 m35.5 m86.5 m
Total assets223 m153 m97.6 m45.8 m94.0 m
Operating cash flow-91.9 m-104 m-51.7 m-51.8 m-45.8 m
Investments (capex)00400
Free cash-flow-91.9 m-104 m-51.7 m-51.8 m-45.8 m
Share buybacks00000
Dividends paid00000

Amounts in USD, currency of the published accounts.

Trailing 12-month ratios

Price / earnings (P/E)-5.62 x
Price / book value2.41 x
Return on Equity (ROE)-37.2 %
Return on Invested Capital (ROIC)-34.4 %
Net margin0.0 %
Debt / equity0.00 x
Current ratio26.37 x
Free cash-flow yield-11.7 %

Altman Z: default risk estimated from the balance sheet and earnings. Piotroski: 9 tests on profitability, debt and efficiency. DCF: estimated value from discounted future cash flows, a model and not a forecast. Source: annual accounts published by the company, data as of 16/11/2026.

+

Analyst consensus and forecasts

What the financial analysts covering Relmada Therapeutics, Inc. publish: ratings, price targets and earnings forecasts.

Majority rating
buy
8 analysts

Breakdown of ratings

strong buy 0buy 5hold 2sell 1strong sell 0

Price targets: published for companies listed in the United States only.

Track record against expectations: reported EPS above consensus 6 times over the last 12 releases.

Source: ratings and forecasts published by analysts, collected on 14/11/2026. An analyst rating or target is not a guarantee.

+

Who owns the stock

Free float, institutional investors, large funds, executives and elected officials: declared positions in Relmada Therapeutics, Inc.

Large funds tracked
20
hold the stock as of 2026Q2
Executives (insiders)
4 / 0
4 purchases, 0 sales in 130 days

Large funds tracked

FundSharesValue (USD)Weight in the fundChangeQuarter
BlackRock7.4 m51.4 m0.0 %+475.9 %2026Q2
State Street5.0 m34.8 m0.0 %+1,310.2 %2026Q2
Adage Capital Partners4.8 m33.0 m0.1 %0.0 %2026Q2
Geode Capital Management2.5 m17.3 m0.0 %+193.7 %2026Q2
Millennium Management2.4 m16.3 m0.0 %-39.6 %2026Q2
Marshall Wace2.2 m15.5 m0.0 %-49.9 %2026Q2
Citadel Advisors2.1 m14.7 m0.0 %n/a2026Q2
Vanguard Group1.2 m5.8 m0.0 %+187.5 %2025Q4

Latest insider transactions

DatePersonSideAmount
10/09/2026Shenouda Magedpurchase339,150 USD
10/09/2026Traversa Sergiopurchase410,000 USD
09/09/2026Shenouda Magedpurchase504,840 USD
09/09/2026Traversa Sergiopurchase418,000 USD

Sources: 13F filings (quarter shown), executives' Form 4 filings and US Congress members' disclosures, collected on 16/11/2026. Detailed disclosure obligations mainly apply to companies listed in the United States.

+

PEA and practical information

PEA eligibility
no
head office outside the EU and EEA
Listing exchange
Nasdaq
IPO: 20/06/2014
ISIN code
US75955J4022
Workforce
17
full-time employees
Chief executive
Sergio Traversa

Rule applied: the French PEA accepts shares of companies headquartered in the European Union or the European Economic Area and subject to corporate income tax; ADRs and tax-exempt property companies (SIIC) are excluded. The institution holding the PEA confirms eligibility.

?

Frequently asked questions about Relmada Therapeutics, Inc.

What is the Relmada Therapeutics, Inc. share price?

Latest recorded price: 4.21 USD on 13/11/2026, for a market cap of 449 m USD.

What is the revenue of Relmada Therapeutics, Inc.?

5,129 USD for fiscal year 2013, with net income of -45,015 USD (net margin -877.7 %).

What do analysts say about Relmada Therapeutics, Inc.?

Out of 8 analysts: 5 buy or strong buy, 2 hold, 1 sell or strong sell.

Is Relmada Therapeutics, Inc. stock eligible for the French PEA?

No: the company is headquartered outside the European Union and the European Economic Area (ISIN US75955J4022).

How many employees does Relmada Therapeutics, Inc. have?

17 full-time employees according to the latest published profile.

Who runs Relmada Therapeutics, Inc.?

Sergio Traversa is the company's chief executive.

Which large funds own Relmada Therapeutics, Inc.?

As of 2026Q2, among the large funds tracked: BlackRock, State Street, Adage Capital Partners, Geode Capital Management, Millennium Management.

07

Similar stocks